Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Zidovudine Zidovudine AUC 0.72 Zidovudine and Viramune can be
100-200 mg TID (0.60-0.96) co-administered without dose
Zidovudine Cmin ND adjustments
Zidovudine Cmax 0.70 (0.49-1.04)
Granulocytopenia is commonly
Nevirapine: Zidovudine had no associated with zidovudine.
effect on its pharmacokinetics. Therefore, patients who receive
nevirapine and zidovudine
concomitantly and especially
paediatric patients and patients
who receive higher zidovudine
doses or patients with poor bone
marrow reserve, in particular those
with advanced HIV disease, have
an increased risk of
granulocytopenia. In such patients
haematological parameters should
be carefully monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Zidovudine Zidovudine AUC 0.72 Zidovudine and Viramune can be
100-200 mg TID (0.60-0.96) co-administered without dose
Zidovudine Cmin ND adjustments
Zidovudine Cmax 0.70 (0.49-1.04)
Granulocytopenia is commonly
Nevirapine: Zidovudine had no associated with zidovudine.
effect on its pharmacokinetics. Therefore, patients who receive
nevirapine and zidovudine
concomitantly and especially
paediatric patients and patients
who receive higher zidovudine
doses or patients with poor bone
marrow reserve, in particular those
with advanced HIV disease, have
an increased risk of
granulocytopenia. In such patients
haematological parameters should
be carefully monitored.
NNRTIs
Efavirenz Efavirenz AUC 0.72 (0.66-0.86) It is not recommended to co-
600 mg QD Efavirenz Cmin 0.68 (0.65-0.81) administer efavirenz and Viramune
Efavirenz Cmax 0.88 (0.77-1.01) (see section 4.4), because of
additive toxicity and no benefit in
terms of efficacy over either
NNRTI alone (for results of 2NN
study, see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
58
Zidovudine Zidovudine AUC 0.72 Zidovudine and Viramune can be
100-200 mg TID (0.60-0.96) co-administered without dose
Zidovudine Cmin ND adjustments
Zidovudine Cmax 0.70 (0.49-1.04)
Granulocytopenia is commonly
Nevirapine: Zidovudine had no associated with zidovudine.
effect on its pharmacokinetics. Therefore, patients who receive
nevirapine and zidovudine
concomitantly and especially
paediatric patients and patients
who receive higher zidovudine
doses or patients with poor bone
marrow reserve, in particular those
with advanced HIV disease, have
an increased risk of
granulocytopenia. In such patients
haematological parameters should
be carefully monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage fd550eb5362a226517df7ba6fa5f2d235d4e7050c6e68db3d84ff024d025c05f · Zeichen 3407–4873 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.